1XVP image
Deposition Date 2004-10-28
Release Date 2004-12-28
Last Version Date 2024-02-14
Entry Detail
PDB ID:
1XVP
Title:
crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid and CITCO
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.60 Å
R-Value Free:
0.23
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 32 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Retinoic acid receptor RXR-alpha
Gene (Uniprot):RXRA
Chain IDs:A, C
Chain Length:236
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Orphan nuclear receptor NR1I3
Gene (Uniprot):NR1I3
Chain IDs:B, D
Chain Length:246
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:nuclear receptor coactivator 1 isoform 1
Chain IDs:E, F, G, H
Chain Length:13
Number of Molecules:4
Biological Source:Homo sapiens
Primary Citation
A Structural Basis for Constitutive Activity in the Human CAR/RXRalpha Heterodimer.
Mol.Cell 16 919 928 (2004)
PMID: 15610735 DOI: 10.1016/j.molcel.2004.11.042

Abstact

The X-ray crystal structure of the human constitutive androstane receptor (CAR, NR1I3)/retinoid X receptor alpha (RXRalpha, NR2B1) heterodimer sheds light on the mechanism of ligand-independent activation of transcription by nuclear receptors. CAR contains a single-turn Helix X that restricts the conformational freedom of the C-terminal AF2 helix, favoring the active state of the receptor. Helix X and AF2 sit atop four amino acids that shield the CAR ligand binding pocket. A fatty acid ligand was identified in the RXRalpha binding pocket. The endogenous RXRalpha ligand, combined with stabilizing interactions from the heterodimer interface, served to hold RXRalpha in an active conformation. The structure suggests that upon translocation, CAR/RXRalpha heterodimers are preorganized in an active conformation in cells such that they can regulate transcription of target genes. Insights into the molecular basis of CAR constitutive activity can be exploited in the design of inverse agonists as drugs for treatment of obesity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures